PRMT5 and cancer: Indeed, PRMT inhibitors, especially inhibitors for PRMT1 and PRMT5 due to their established involvement in cancer progression, are currently being explored as therapeutics for hematological malignancies and solid tumors and have entered clinical trials (www.clinicaltrails.gov, accessed on 16 February 2024).